Which of the following is a new drug that acts by inhibiting PCSK9?
Monoclonal Antibodies that target PCSK9: Alirocumab and Evolocumab. Pro protein convease subtilisin Kexan type 9 (PCSK9) is a protein that binds LDL receptors and transpo them to lysosomes where these are degraded . Therefore instead of recycling of LDL receptor to surface of hepatocytes they get destroyed. Inhibitors of PCSK9 therefore prevent destruction of LDL receptor resulting in lowering of LDL cholesterol.
Reslizumab
Brodalumab
Alirocumab
Ixekizumab
Hypeension, Arrhythmias, Dyslipidemia